Skip to main content

Zura Bio Ltd

corporate_fare Company Profile

Zura Bio Ltd

ZURA·NASDAQ·Life Sciences·CIK 0001855644

Zura Bio Ltd is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases. The company's strategy involves identifying immune-mediated diseases where translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis. Zura Bio Ltd focuses on targets for which human data, including biomarker findings, genetic associations, and prior clinical studies, inform therapeutic rationale and development decisions. The company seeks to advance product candidates in therapeutic areas with meaningful unmet medical need and potential for commercial relevance if clinical benefit is demonstrated. Zura Bio Ltd has in-licensed three clinical-stage product candidates. These include Tibulizumab (ZB-106), a humanized bispecific antibody engineered to bind and neutralize interleukin-17A ("IL-17A") and B cell activating factor ("BAFF") within a single therapeutic molecule. The second is Crebankitug (ZB-168), a fully human immunoglobulin G1 ("IgG1") monoclonal antibody targeting interleukin-7 receptor alpha ("IL-7Rα"). The third product candidate is Torudokimab (ZB-880), a fully human immunoglobulin G4 ("IgG4") monoclonal antibody targeting interleukin-33 ("IL-33"). Currently, Zura Bio Ltd is conducting two global Phase 2 clinical trials evaluating tibulizumab in adult participants, each with an optional open-label extension. These trials are TibuSHIELD in hidradenitis suppurativa ("HS") and TibuSURE in diffuse cutaneous systemic sclerosis ("dcSSc"). Crebankitug and torudokimab were previously evaluated in early-stage clinical trials by third parties before Zura Bio Ltd in-licensed their development rights. The company is assessing potential future development strategies for these product candidates based on available clinical and translational data. Zura Bio Ltd has not completed any Phase 2 or Phase 3 clinical trials and has no products approved for commercial sale. Autoimmune and inflammatory diseases collectively affect millions of individuals worldwide.

Zura Bio Ltd (NASDAQ:ZURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ZURA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Zura Bio Restructures Key Agreements with Significant Equity Issuance and Cash Payments

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$68.65M
Diluted EPS
-$1.06
Op. Cash Flow
-$64.81M
Free Cash Flow
-$64.93M
Operating Income
-$75.25M
Cash & Equivalents
$109.41M
Debt / Equity
0.00×
Shares Outstanding
73.68M sh
Source: 10-K · filed 2026-03-19 · accession 0001104659-26-032080
$0.9301 -0.04% today
52-week range · as of 2026-11-09 $0.9301 – $7.44
Market cap
$89.63M
Volume
4.8M (0.7× avg)
3-mo avg 7.2M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZURA - Filings & News (Page 2)

ZURA
Jan 02, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.55
Real-time Price: $0.9301 info
Change: -$4.62 (-83%) info
Market Cap: $89.631M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets